Results 31 to 40 of about 839,337 (241)
Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021
MMWR. Morbidity and mortality weekly report, 2021 Messenger RNA (mRNA) BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) COVID-19 vaccines have been shown to be effective in preventing symptomatic COVID-19 in randomized placebo-controlled Phase III trials (1,2); however, the benefits of these vaccines ...M. Thompson, J. Burgess, A. Naleway, Harmony L. Tyner, Sarang K. Yoon, J. Meece, Lauren E. W. Olsho, A. Caban-Martinez, A. Fowlkes, K. Lutrick, J. Kuntz, K. Dunnigan, M. Odean, K. Hegmann, Elisha L Stefanski, Laura J. Edwards, Natasha Schaefer-Solle, L. Grant, K. Ellingson, H. Groom, Tnelda Zunie, M. Thiese, L. Ivacic, Meredith G. Wesley, Julie Mayo Lamberte, Xiaoxiao Sun, Michael E. Smith, Andrew L. Phillips, Kimberly D. Groover, Young M. Yoo, J. Gerald, Rachel T. Brown, Meghan K Herring, G. Joseph, S. Beitel, Tyson Morrill, Josephine Mak, P. Rivers, K. Harris, D. Hunt, Melissa L. Arvay, P. Kutty, A. Fry, M. Gaglani +43 moresemanticscholar +1 more sourceEvaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents
New England Journal of Medicine, 2021 Background The incidence of coronavirus disease 2019 (Covid-19) among adolescents between 12 and 17 years of age was approximately 900 per 100,000 population from April 1 through June 11, 2021.Kashif Ali, G. Berman, Honghong Zhou, Weiping Deng, Veronica Faughnan, Maria Coronado-Voges, B. Ding, J. Dooley, B. Girard, William Hillebrand, R. Pajon, Jacqueline M. Miller, B. Leav, R. McPhee +13 moresemanticscholar +1 more sourceImmunogenicity and reactogenicity of heterologous and homologous mRNA-1273 and BNT162b2 vaccination: A multicenter non-inferiority randomized trial
EClinicalMedicine, 2022 Summary: Background: Although effective mRNA vaccines for SARS-CoV-2 infection have been deployed worldwide, their interchangeability could facilitate the scale-up of vaccination programs.Cécile Janssen, Marine Cachanado, Laetitia Ninove, Marie Lachatre, Jocelyn Michon, Olivier Epaulard, Zoha Maakaroun-Vermesse, Christian Chidiac, Bruno Laviolle, Hugues Aumaitre, Ady Assaf, Karine Lacombe, Catherine Schmidt-Mutter, Elisabeth Botelho-Nevers, Magali Briere, Thomas Boisson, Paul Loubet, Boris Bienvenu, Olivier Bouchaud, Amel Touati, Christine Pereira, Alexandra Rousseau, Laurence Berard, Melissa Montil, Xavier de Lamballerie, Tabassome Simon, Odile Launay +26 moredoaj +1 more sourceSafety Following COVID-19 Booster Vaccine with BNT162b2 Compared to mRNA-1273 in Solid Cancer Patients Previously Vaccinated with ChAdOx1 or CoronaVac
Vaccines, 2023 Safety data following the COVID-19 booster mRNA vaccine in solid cancer patients are scarce. We prospectively evaluated adverse events after a booster dose of the BNT162b2 vaccine as compared to the mRNA-1273 vaccine in solid malignancy patients who had ...Passakorn Wanchaijiraboon, Panot Sainamthip, Nattaya Teeyapun, Sutima Luangdilok, Yong Poovorawan, Nasamon Wanlapakorn, Suebpong Tanasanvimon, Virote Sriuranpong, Thiti Susiriwatananont, Nicha Zungsontiporn, Nussara Pakvisal +10 moredoaj +1 more sourcemRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants
bioRxiv, 2021 Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is the causative infection of a global pandemic that has led to more than 2 million deaths worldwide.Kai Wu, Anne P. Werner, Juan I. Moliva, M. Koch, A. Choi, Guillaume B. E. Stewart-Jones, H. Bennett, Seyhan Boyoglu-Barnum, W. Shi, B. Graham, A. Carfi, Kizzmekia S. Corbett, R. Seder, D. Edwards +13 moresemanticscholar +1 more sourceType of mRNA COVID-19 vaccine and immunomodulatory treatment influence humoral immunogenicity in patients with inflammatory rheumatic diseases [PDF]
, 2022 Patients with inflammatory rheumatic diseases (IRD) are at increased risk for worse COVID-19 outcomes. Identifying whether mRNA vaccines differ in immunogenicity and examining the effects of immunomodulatory treatments may support COVID-19 vaccination ...Andrey, Diego O, Berger, Christoph T, Ciurea, Adrian, Finckh, Axel, Lauper, Kim, Lescuyer, Pierre, Maletic, Tanja, Möller, Burkhard, Polysopoulos, Christos, Raptis, Catherine E, Riek, Myriam, Rubbert-Roth, Andrea, Safford, Judith, Scherer, Almut, von Loga, Isabell, Vuilleumier, Nicolas +15 morecore +6 more sourcesTrajectory of IgG to SARS-CoV-2 After Vaccination With BNT162b2 or mRNA-1273 in an Employee Cohort and Comparison With Natural Infection
Frontiers in Immunology, 2022 Three COVID-19 vaccines have received FDA-authorization and are in use in the United States, but there is limited head-to-head data on the durability of the immune response elicited by these vaccines.Behnam Keshavarz, Nathan E. Richards, Lisa J. Workman, Jaimin Patel, Lyndsey M. Muehling, Glenda Canderan, Deborah D. Murphy, Savannah G. Brovero, Samuel M. Ailsworth, Will H. Eschenbacher, Emily C. McGowan, Barbara J. Mann, Michael R. Nelson, Alexandra Kadl, Alexandra Kadl, Judith A. Woodfolk, Thomas A.E. Platts-Mills, Jeffrey M. Wilson +17 moredoaj +1 more sourceEfficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
New England Journal of Medicine, 2020 Background Vaccines are needed to prevent coronavirus disease 2019 (Covid-19) and to protect persons who are at high risk for complications. The mRNA-1273 vaccine is a lipid nanoparticle–encapsulated mRNA-based vaccine that encodes the prefusion ...L. Baden, Hana M. El Sahly, B. Essink, K. Kotloff, S. Frey, R. Novak, D. Diemert, S. Spector, N. Rouphael, C. Creech, J. Mcgettigan, Shishir Kehtan, N. Segall, Joel Solis, A. Brosz, C. Fierro, H. Schwartz, K. Neuzil, L. Corey, P. Gilbert, H. Janes, D. Follmann, M. Marovich, J. Mascola, L. Polakowski, J. Ledgerwood, B. Graham, H. Bennett, R. Pajon, C. Knightly, B. Leav, W. Deng, Honghong Zhou, Shu Han, M. Ivarsson, Jacqueline M. Miller, T. Zaks +36 moresemanticscholar +1 more sourceSafety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
New England Journal of Medicine, 2020 Background Testing of vaccine candidates to prevent infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in an older population is important, since increased incidences of illness and death from coronavirus disease 2019 (Covid-19 ...E. Anderson, N. Rouphael, A. Widge, L. Jackson, P. Roberts, M. Makhene, J. Chappell, M. Denison, Laura J. Stevens, A. Pruijssers, A. McDermott, B. Flach, Bob C. Lin, N. Doria-Rose, S. O'Dell, S. Schmidt, Kizzmekia S. Corbett, P. Swanson, M. Padilla, K. Neuzil, H. Bennett, B. Leav, M. Makowski, J. Albert, Kaitlyn A. Cross, V. Edara, K. Floyd, M. Suthar, David R. Martinez, R. Baric, Wendy L. Buchanan, C. Luke, Varun K. Phadke, C. Rostad, J. Ledgerwood, B. Graham, J. Beigel +36 moresemanticscholar +1 more source
